The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis
Z Wang, X Jin, J Zeng, Z Xiong, X Chen - Annals of Hematology, 2024 - Springer
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and
allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with …
allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with …
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by …
VWK Li, R Yim, P Lee, L Chin, L Au, GMK Leung… - Annals of …, 2023 - Springer
Relapse after allogeneic haematopoietic stem cell transplantation (HSCT) is one of the key
determinants of outcome in myelofibrosis (MF) and remains an important unmet need. In this …
determinants of outcome in myelofibrosis (MF) and remains an important unmet need. In this …